Initiating insulin therapy in elderly patients with Type 2 diabetes: Efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents

Diabetic Medicine

Volumn 26, Issue 11, 2009, Pages 1147-1155

  Wolffenbuttel, B H R ^a   Klaff, L J ^b   Bhushan, R ^c   Fahrbach, J L ^d   Jiang, H ^d   Martin, S ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Rainier Clinical Research Center   (United States)

^c Metabolic Center of Louisiana Research Foundation   (United States)

^d Lilly USA   (United States)

Author keywords

Elderly; Glargine; Insulin analogues; Lispro; Mix 25

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HEART ARREST; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEIZURE;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 70350754378     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02824.x     Document Type: Article

References (36)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 : 1047 1053.
2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008 31 : S12 S54.
3. California Healthcare Foundation, American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003 51 : S265 S280.
4. Halter JB, Kennedy L, Herman WH, Miller MF. Glycemic control and safety of glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): the GOAL A1C study Abstract from the annual meeting of the American Diabetes Association, 9-13 June 2006. Washington, D.C. Diabetes 2006 55 (suppl 1 A114.
5. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007 55 : 182 188.
6. Papa G, Fedele V, Chiavetta A, Lorenti I, Leotta C, Luca S et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008 45 : 53 59.
7. Herz M, Sun B, Milicevic Z, Erickson P, Fovenyi J, Grzywa M et al. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther 2002 24 : 73 86.
8. Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004 66 : 23 29.
9. ® study. Diabetes Obes Metab 2009 11 : 20 26.
10. Fahrbach J, Jacober S, Jiang H, Martin S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol 2008 5 : 831 838.
11. 1c and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009 94 : 1689 1694.
12. Buse JB, Wolffenbuttel BHR, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL et al. The DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009 32 : 1007 1013.
13. Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR 3rd. et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006 12 : S6 S12.
14. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005. Available at http://www.idf.org/Global-guideline Last accessed 2 June 2009.
15. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr., Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005 23 : 78 86.
16. Fritsche A, Schweitzer MA, Haring HU, the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003 138 : 952 959.
17. ADA. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005 28 : 1245 1249.
18. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007 357 : 1716 1730.
19. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005 22 : 374 381.
20. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004 26 : 2034 2044.
21. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 265.
22. Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson L, Marinopoulos SS et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008 149 : 549 560.
23. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
24. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 28 : 103 117.
25. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 : 2560 2572.
26. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
27. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003 163 : 1306 1316.
28. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of US adults. Diabetes Care 2001 24 : 1397 1402.
29. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type 2 diabetes: the epidemiological evidence. Diabetologia 2001 44 : 2107 2114.
30. International Diabetes Federation. Guidelines for post-meal glucose management. 2007. Brussels : International Diabetes Federation, 2007. Available at http://www.idf.org/guideline-postmeal Last accessed 2 June 2009.
31. Nishimura H, Shintani M, Maeda K, Hanaoka I, Kuzuya H. Does multiple injection therapy with a rapid-acting insulin analogue prevent cardiovascular disease in type 2 diabetes? The NICE study: a prospective, randomised, open-label, blinded endpoint study. Rome : Poster from the annual meeting of the European Association for the Study of Diabetes, 7-11 September 2008 : 1349.
32. Raz I, Wilson PWF, Strojek K, Kowalska I, Bozikov V, Gitt AK et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009 32 : 381 386.
33. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005 28 : 2948 2961.
34. Kyllastinen M, Groop L. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Ann Clin Res 1985 17 : 100 104.
35. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996 156 : 259 264.
36. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998 21 : 1052 1057.